-

Applied BioCode Announces Distribution Agreement with Henry Schein

Partnership Expands Access to the BioCode® MDx-3000 System for Hospitals and Reference Laboratories

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu.

"Helping broaden access to advanced molecular diagnostic capabilities"

Share

The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal infection panels, with a customizable menu option, enabling laboratories to deliver accurate, cost-effective, and efficient molecular diagnostic testing.

Through this agreement, Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories nationwide, helping broaden access to advanced molecular diagnostic capabilities.

"Applied BioCode is excited to partner with Henry Schein as we continue expanding our presence in hospitals and reference laboratories across the United States," said Jim Leigh, Sr. Vice President of Sales. "Henry Schein's extensive laboratory distribution network makes them an ideal partner to help bring our innovative molecular diagnostic solutions to more clinical laboratories."

Applied BioCode remains committed to advancing molecular diagnostics through innovative technologies that improve laboratory workflows and deliver accurate, reliable, and actionable results for healthcare providers and patients.

About Applied BioCode

Applied BioCode is a leading provider of molecular diagnostic solutions, focused on developing innovative technologies that empower clinical laboratories, improve operational efficiency, and enhance patient care.

To learn more about Applied BioCode's molecular diagnostic solutions, visit:

https://www.apbiocode.com/products/.

Contacts

Applied BioCode
communications@apbiocode.com

Industry:

Applied BioCode

TWSE:6598
Release Versions
English
Hashtags
#ClinicalDiagnostics
#DiagnosticTesting
#MolecularDiagnostics
#MolecularPanels
#MultiplexTesting

Contacts

Applied BioCode
communications@apbiocode.com

Social Media Profiles
Applied BioCode on LinkedIn
More News From Applied BioCode

Applied BioCode Reports Record Financial Results for the First Half of 2026; Revenue Increases 81% Year Over Year, Driven by Strong U.S. Molecular Diagnostics Growth

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, Inc., a leader in high-throughput multiplex molecular diagnostics, today announced financial results for the six months ended June 30, 2026. For the six months ended June 30, 2026, the Company reported consolidated revenue of $13.59 million, an 81% increase from the same period in 2025. This performance was driven by expansion of the Company's installed base in U.S. clinical and veterinary laboratories and increased utilization of its...

Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD Use

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in multiplex molecular diagnostic solutions, today announced a significant enhancement to its BioCode® Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher™ Flex platform. This expansion provides clinical laboratories running BioCode® RPP with greater workflow flexibility and optimized sample processing capabilities. This enhanceme...

Applied BioCode Submits BioCode® Respiratory Pathogen Panel (RPP) with KingFisher™ Nucleic Acid Extraction Claim to the FDA

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the KingFisher™ Flex Nucleic Acid Purification System in combination with the BioCode® Respiratory Pathogen Panel (RPP). This submission is aimed at expanding the use of the BioCode® RPP, enabling laboratories to further streamline workflows while maintaining high-quality, reliable results. The new submission...
Back to Newsroom